Jorgensen Andrea L, Orrell Catherine, Waitt Catriona, Toh Cheng-Hock, Sekaggya-Wiltshire Christine, Hughes Dyfrig A, Allen Elizabeth, Okello Emmy, Tatz Gayle, Culeddu Giovanna, Asiimwe Innocent G, Semakula Jerome Roy, Mouton Johannes P, Cohen Karen, Blockman Marc, Lamorde Mohammed, Pirmohamed Munir
Department of Health Data Science, Institute of Population Health Sciences, University of Liverpool, Liverpool, United Kingdom.
Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
JMIR Res Protoc. 2023 Jul 19;12:e46710. doi: 10.2196/46710.
The quality of warfarin anticoagulation among Sub-Saharan African patients is suboptimal. This is due to several factors, including a lack of standardized dosing algorithms, difficulty in providing timely international normalized ratio (INR) results, a lack of patient feedback on their experiences with treatment, a lack of education on adherence, and inadequate knowledge and training of health care workers. Low quality of warfarin anticoagulation, expressed as time in therapeutic range (TTR), is associated with higher adverse event rates, including bleeding and thrombosis, and ultimately, increased morbidity and mortality. Processes and interventions that improve this situation are urgently needed.
This study aims to evaluate the implementation of the "warfarin bundle," a package of interventions to improve the quality of anticoagulation and thereby clinical outcomes. The primary outcome for this study is TTR over the initial 3 months of warfarin therapy.
Patients aged 18 years or older who are newly initiated on warfarin for venous thromboembolism, atrial fibrillation, or valvular heart disease will be enrolled and followed up for 3 months at clinics in Cape Town, South Africa, and Kampala, Uganda, where the warfarin bundle is implemented. A retrospective review of the clinical records of patients on warfarin treatment before implementation (controls) will be used for comparison. This study uses a mixed methods approach of the implementation of patient- and process-centered activities to improve the quality of anticoagulation. Patient-centered activities include the use of clinical dosing algorithms, adherence support, and root cause analysis, whereas process-centered activities include point-of-care INR testing, staff training, and patient education and training. We will assess the impact of these interventions by comparing the TTR and safety outcomes across the 2 groups, as well as the cost-effectiveness and acceptability of the package.
We started recruitment in June 2021 and stopped in August 2022, having recruited 167 participants. We obtained ethics approval from the University of Cape Town Faculty of Health Sciences Human Research Ethics Committee, the Provincial Health Research Committees in South Africa, the Joint Clinical Research Centre Institutional Review Board, Kampala, and the University of Liverpool Research Ethics Committee. As of February 2023, data cleaning and formal analysis are underway. We expect to publish the full results by December 2023.
We anticipate that the "bundle of care," which includes a clinical algorithm to guide individualized dosing of warfarin, will improve INR control and TTR of patients in Uganda and South Africa. We will use these findings to design a larger, multisite clinical trial across several Sub-Saharan African countries.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/46710.
撒哈拉以南非洲患者华法林抗凝治疗的质量欠佳。这是由多种因素导致的,包括缺乏标准化的给药算法、难以及时提供国际标准化比值(INR)结果、患者缺乏对治疗体验的反馈、缺乏关于依从性的教育以及医护人员的知识和培训不足。华法林抗凝治疗质量低下,以治疗范围内时间(TTR)表示,与更高的不良事件发生率相关,包括出血和血栓形成,最终导致发病率和死亡率增加。迫切需要改善这种情况的流程和干预措施。
本研究旨在评估“华法林综合干预措施”的实施情况,这是一套旨在提高抗凝质量从而改善临床结局的干预措施。本研究的主要结局是华法林治疗最初3个月的TTR。
年龄在18岁及以上、因静脉血栓栓塞、心房颤动或心脏瓣膜病新开始使用华法林治疗的患者将被纳入研究,并在南非开普敦和乌干达坎帕拉实施华法林综合干预措施的诊所进行3个月的随访。将对实施前接受华法林治疗患者(对照组)的临床记录进行回顾性分析以作比较。本研究采用混合方法,实施以患者和流程为中心的活动以提高抗凝质量。以患者为中心的活动包括使用临床给药算法、依从性支持和根本原因分析,而以流程为中心的活动包括即时检验INR、工作人员培训以及患者教育和培训。我们将通过比较两组的TTR和安全性结局,以及该综合干预措施的成本效益和可接受性来评估这些干预措施的影响。
我们于2021年6月开始招募,2022年8月停止,共招募了167名参与者。我们获得了开普敦大学健康科学学院人类研究伦理委员会、南非省级健康研究委员会、坎帕拉联合临床研究中心机构审查委员会以及利物浦大学研究伦理委员会的伦理批准。截至2023年2月,数据清理和正式分析正在进行中。我们预计在2023年12月公布完整结果。
我们预计包括指导华法林个体化给药临床算法的“护理综合干预措施”将改善乌干达和南非患者的INR控制和TTR。我们将利用这些研究结果设计一项覆盖多个撒哈拉以南非洲国家的更大规模多中心临床试验。
国际注册报告识别码(IRRID):DERR1-10.2196/46710。